Determinants of primaquine and carboxyprimaquine exposures in children and adults with

***Plasmodium vivax* malaria**

Running title: **Primaquine exposures in vivax malaria**

Cindy S Chu[1,2], James A Watson[2,3,]*, Aung Pyae Phyo[1], Htun Htun Win[1], Widi Yotyingaphiram[1], Suradet

Thinraow[1], Nay Lin Soe[1], Aye Aye Aung[1], Pornpimon Wilaisrisak[1], Kanokpich Puaprasert[4], Mallika Imwong[4],

Warunee Hanpithakpong[3], Daniel Blessborn[2,3], Joel Tarning[2,3], Stéphane Proux[1], Clare Ling[1,2], François H

Nosten[1,2], Nicholas J White[2,3]

[1] Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical

Medicine, Mahidol University, Mae Sot, Thailand

[2] Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of

Oxford, Oxford, UK

[3] Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,

Bangkok, Thailand

[4] Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol

University, Bangkok, Thailand.

Keywords: *Plasmodium vivax*, primaquine, pharmacokinetics, relapse, chloroquine,

dihydroartemisinin-piperaquine

Corresponding author: james@tropmedres.ac

Abstract

Background

Primaquine is the only widely available drug for radical cure of *Plasmodium vivax* malaria. There

is uncertainty whether the pharmacokinetic properties of primaquine are altered significantly in

childhood or not.

Methods

Glucose-6-phosphate dehydrogenase normal patients with uncomplicated *P. vivax* malaria were

randomized to receive either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine

(dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine; given either as 0.5 mg

base/kg/day for 14 days or 1 mg/kg/day for 7 days. Pre-dose day 7 venous plasma

concentrations of chloroquine, desethylchloroquine, piperaquine, primaquine and

carboxyprimaquine were measured. Methemoglobin levels were measured either daily or on

days 1, 3, 6 and 13, and additionally on day 10 in the primaquine 14-day groups.

Results

Day 7 primaquine and carboxyprimaquine concentrations were available for 641 patients. After

adjustment for the primaquine mg/kg daily dose, day of sampling, partner drug, and fever

clearance, there was a significant non-linear relationship between age and trough primaquine

and carboxyprimaquine concentrations, and day methemoglobin levels. Compared to adults 30

years of age, children 5 years of age had trough primaquine concentrations 0.53 (95% CI: 0.39-

0.73) fold lower, trough carboxyprimaquine concentrations 0.45 (95% CI: 0.35- 0.55) fold lower,

and day 7 methemoglobin levels 0.87 (95% CI: 0.58-1.27) fold lower. Increasing concentrations

of piperaquine and chloroquine and poor metabolizer *CYP 2D6* alleles were associated with

higher day 7 primaquine and carboxyprimaquine concentrations. Higher blood methemoglobin

concentrations were associated with a lower risk of recurrence.

Conclusion

Young children have lower primaquine and carboxyprimaquine exposures, and lower levels of

methemoglobinemia, than adults. Young children may need higher weight adjusted primaquine

doses than adults.

Introduction

Primaquine is used for radical cure of *Plasmodium vivax* and *Plasmodium ovale* malaria, for antimalarial chemoprophylaxis and as a single dose gametocytocide in *Plasmodium falciparum* malaria (1). Although the slowly eliminated 8-aminoquinoline tafenoquine has been registered in a few countries for radical cure or chemoprophylaxis in adults, and pamaquine and quinocide were once used, primaquine is by far the most widely deployed drug in this class. It is generally agreed that the dosing of antimalarial chemotherapy should be designed to provide equivalent exposures to the active antimalarial across the age range (1). There is uncertainty whether or not children have lower exposures to primaquine and its bioactive metabolites than adults for the same weight adjusted doses, and thus whether they should receive higher doses than currently recommended (2–5). Primaquine is combined with either an artemisinin combination treatment (ACT) or chloroquine to prevent relapse of vivax or ovale malaria (radical cure) (1). Primaquine is a pro-drug requiring metabolism to bioactive metabolites mainly via the liver cytochrome P450 isoenzyme *CYP 2D6* (6). The prevalence of intermediate and non-functioning *CYP 2D6* alleles is over 50% in some populations, particularly in Asians (7–9). Decreased *CYP 2D6* function, resulting from intermediate or poor metabolizer genotypes, potentially lowers radical cure efficacy (10, 11).

Chloroquine has been the first-line treatment for the blood stages of *P. vivax* malaria for over 70 years (1). High grade resistance in *P. vivax* remains confined to Oceania and Indonesia (12) but, in the last decade, low grade chloroquine resistance, manifest by earlier appearance of relapses, has been reported increasingly in other locations. Piperaquine (a slowly eliminated bisquinoline), combined with dihydroartemisinin, is a well-tolerated and highly efficacious ACT which provides

an excellent alternative blood stage treatment for *P. vivax* malaria (13). An open label two-way

randomized controlled trial, conducted on the Thailand-Myanmar border, showed previously

that a 7-day high dose primaquine regimen (1 mg/kg/day) , combined either with chloroquine or

dihydroartemisinin-piperaquine, was non-inferior to the standard 14-day (0.5 mg/kg/day)

regimen (14). This large study allowed investigation of the pharmacokinetic properties of

primaquine in adults and children, characterization of the determinants of drug exposures, and

correlation with therapeutic outcomes.

Methods

Clinical trial

This study was conducted by the Shoklo Malaria Research Unit (SMRU), which is located on the

northwest Thailand-Myanmar border. Full details of the study have been reported previously

(14). In brief, patients who presented to an outpatient clinic with microscopy confirmed

uncomplicated *P. vivax* mono-infections were enrolled if they were ≥ 6 months old, and if they

were glucose-6-phosphate dehydrogenase (G6PD) normal by the fluorescent spot test. Patients

were excluded if they were pregnant or breastfeeding an infant ≤ 6 months, had a hematocrit

≤25%, or had received a blood transfusion within 3 months. Written informed consent was

obtained from patients or from parents or carers of children below 18 years old.

Patients were randomized 1:1:1:1 to each of the following groups:

1. Chloroquine (10 mg base/kg on the first two days of treatment, then 5 mg base/kg on day

3; Remedica, Ltd., Cyprus) and primaquine (1 mg base/kg/day for 7 days; Government

Pharmaceutical Organization, Thailand)

2. Chloroquine as above and primaquine (0.5 mg base/kg/day for 14 days)

3. Dihydroartemisinin-piperaquine (dihydroartemisinin 7 mg/kg and piperaquine 55 mg/kg for 3 days; Guilin Pharmaceutical company, China) and primaquine (1 mg base/kg/day for 7 days)

4. Dihydroartemisinin-piperaquine as above plus primaquine (0.5 mg base/kg/day for 14 days)

Food and drink were given before drug administration. Primaquine was usually started on the same day as the schizonticide (i.e. the first day of treatment) but in a subset of patients it was started on the third day of treatment. Patients were assessed daily while on treatment. Methemoglobin was measured either daily or on days 1, 3, 6 and 13, and additionally on day 10 in the primaquine 14-day groups, using a transcutaneous pulse oximeter (Masimo Radical-7®). One recruitment clinic did not have access to a transcutaneous oximeter, so 80 study patients did not have methemoglobin measurements. All drug doses were supervised.

A venous blood sample for antimalarial drug levels was taken before drug administration on day 6 (i.e. the 7th day of treatment) +/- 2 days, and plasma was separated and stored at -70°C. Patients were followed at weeks 2 and 4, and then every 4 weeks until 52 weeks. If there was a *P. vivax* recurrence then a venous plasma blood sample for drug levels was taken again. Standard high dose primaquine (0.5 mg base/kg/day for 14 days) and chloroquine were given for the treatment of recurrences. Follow-up was re-started as if newly recruited, and day 6 sampling for drug levels was collected again. The total study duration was 52 weeks from enrolment.

Drug measurements

Chloroquine/desethylchloroquine, piperaquine, and primaquine/carboxyprimaquine plasma

concentrations were measured using three validated liquid chromatography (LC) – tandem mass

spectrometry (MS/MS) methods (15–17). The lower limits of quantification (LLOQ) were set to

1.4, 1.5, 1.14 and 4.88 ng/mL for chloroquine/desethylchloroquine, piperaquine, primaquine and

carboxyprimaquine, respectively. All three quantification methods were validated according to

regulatory standards and three levels of quality control samples were analyzed in triplicate within

each batch of clinical samples. Total imprecision (i.e. relative standard deviation) for all quality

control samples was below 10% during drug quantification.

CYP 2D6 genotyping

We carried out a nested case-control genotyping study to assess the effect of *CYP 2D6*

polymorphisms on recurrent vivax malaria. Cases were all patients with a recorded recurrent

episode of vivax malaria during follow-up and controls were patients without observed

recurrences matched by age and sex (in total n=158 patients). The *CYP 2D6* gene

duplications/multiplications and gene deletions were determined by extra-long range

polymerase chain reaction (XL-PCR) using a previously published protocol (18). The functional

CYP 2D6 and nonfunctional *CYP2D8* and *CYP2D7* genes were then differentiated by intron 2

sequencing (INT2). The variants *1, *2, *4, *5, *10, *39, and *36 were identified with rapid

identification of four polymorphic loci by allele-specific oligonucleotide probes using real-time

SNPs genotyping. From the *CYP 2D6* genotyping result the *CYP 2D6* "activity score" was obtained

as described previously (15, 19–21).

Ethics approval

This study was approved by both the Mahidol University Faculty of Tropical Medicine Ethics

Committee (MUTM 2011-043, TMEC 11-008) and the Oxford Tropical Research Ethics

Committee (OXTREC 17-11) and was registered at ClinicalTrials.gov (NCT01640574).

Statistical analysis

All drug concentration data were analyzed on the log base 10 scale. Three main generalized

additive linear regression models were fitted to the $\log_{10}$ primaquine day 7 concentrations; the

$\log_{10}$ carboxyprimaquine concentrations; and the $\log_{10}$ carboxyprimaquine to primaquine ratios.

We used the following predictors age (years), mg/kg daily dose of primaquine (the administered

mg/kg dose not the target dose), study arm (DHA-piperaquine versus chloroquine), fever

clearance time (days), the number of days since start of primaquine dosing (6 versus 4), and the

time since the previous primaquine dose (in hours). We excluded drug measurements taken

outside of a 18-30 hour window after the previous dose (only trough levels approximately one

day after dosing), except for those for which the previous dose was given less than 30 minutes

before the drug measurement. More than 90% of samples were taken in this window

(Supplementary Figure 1). A smooth spline term with 3 degrees of freedom was used to estimate

non-linear effects of age. Individual random intercept terms were specified to account for

multiple day 7 measurements in the same patient. To assess any residual effect of *CYP 2D6*

diplotypes, we fitted linear regression models to the model residual concentrations with the *CYP*

2D6 activity score as a linear predictor. To estimate the effect of the partner drug concentrations

(not available for every day 7 measurement), we fitted separate generalized additive regression

models to the primaquine and carboxyprimaquine $\log_{10}$ concentrations with either the $\log_{10}$

chloroquine+desethychloroquine (assuming equal antimalarial activities of parent drug and

metabolite and designated as 'chloroquine' in the remainder of the paper) concentration or the

$\log_{10}$ piperaquine concentration as additional predictors.

We fitted a generalized additive regression model to the day 7 blood methemoglobin

concentrations (expressed as a percentage of the hemoglobin concentration) with age, mg/kg

daily dose of primaquine, study arm (DHA-piperaquine versus chloroquine), fever clearance time

(days), and days since start of primaquine dosing as predictors. A spline term with 3 degrees of

freedom was fit to age. Secondary models included the *CYP 2D6* activity score (available only for

the subset of patients in the nested case control investigation) as an additional covariate, both

on the linear scale and as a binary covariate ($\leq$0.5 versus >0.5). The activity score has an arbitrary

scale so it is unclear how best to encode it in regression models (i.e. an activity score of 2 versus

1 is not the same as 1 versus 0).

We fitted Cox proportional hazard models to the time to first recurrence (right censored event

for patients who did not have a recurrence during follow-up), with continuous predictors: age,

partner schizonticidal drug (chloroquine versus piperaquine), and either the $\log_{10}$ primaquine or

the $\log_{10}$ carboxyprimaquine day 7 concentration (they are highly co-linear so we fitted two

separate models). Additional models included the day 7 methemoglobin levels as an additional

predictor (measured in all sites except the one where a transcutaneous pulse oximeter was not

available).

The generalized additive models were fitted in R version 4.0.2 using the package *mgcv* version

1.8. The Cox proportional hazard model used the *survival* package version 3.2. Code in the form

of an RMarkdown script along with all analyzed data are available on an accompanying github

repository for full reproducibility (https://github.com/jwatowatson/Primaquine_day7).

Results

Between February 2012 and July 2014, 680 patients with uncomplicated acute *P. vivax* malaria

were enrolled. In total 641 patients had at least one day 7 plasma primaquine and

carboxyprimaquine concentration measured, either during the enrollment episode or during a

recurrent *P. vivax* episode (there were a total of 720 episodes with day 7 concentrations including

patients with multiple episodes). For 692 of these day 7 concentrations, the corresponding

plasma chloroquine or piperaquine concentration was also available (measured from the same

blood sample). We excluded 41 drug measurements considered not to be trough levels (see

Methods) resulting in a total of 679 day 7 measurements included in the analysis.

In total, 71 of the patients with measured primaquine and carboxyprimaquine concentrations

were 6 to ≤10 years of age (median weight 20kg, range 13-30kg), and 34 were ≤5 years of age

(median weight 14kg, range 8-20kg) (Table 1). Three patients were less than 3 years old, and the

youngest was 1 year 6 months old. Fever and parasite clearance times were similar across all age

groups. The proportion of patients with microscopy detected gametocytemia was higher in the

older age groups >10 years.

Effect of age

After adjustment for the daily mg/kg primaquine dose, the number of days of dosing, the fever

clearance times, and the partner drug (piperaquine versus chloroquine), there was a significant

non-linear association between age and day 7 primaquine trough concentration ($p<10^{-16}$ for the

smooth spline term fit to age) and day 7 carboxyprimaquine trough concentration ($p<10^{-16}$ for

the smooth spline term fit to age) (Figure 1). For both primaquine and carboxyprimaquine,

increasing age correlated with higher trough levels. The strongest effect was seen for the

carboxyprimaquine trough levels. Thus the ratio of carboxyprimaquine to primaquine was also

associated with age, with an approximate doubling when comparing patients aged $\leq$5 years

versus patients 30 years or older (Figure 1).

Effect of partner drug

Our previously reported healthy volunteer studies showed that co-administration of piperaquine

and chloroquine both increased exposures to primaquine and carboxyprimaquine (15, 16). In this

study of patients with vivax malaria, a ten-fold increase in the chloroquine day 7 concentration

was associated with a 2.5 fold increase in day 7 primaquine concentrations (95% CI: 1.9 to 3.1;

p=0.0003), and a 2.0 fold increase in day 7 carboxyprimaquine concentrations (95% CI: 1.7 to 2.4;

p=0.0002). A ten-fold increase in the piperaquine day 7 concentrations was associated with a 2.5

fold increase in primaquine concentrations (95% CI: 1.9 to 3.2; p=0.0005), and a 2.5 fold increase

in carboxyprimaquine concentrations on day 7 (95% CI: 2.1 to 3.0; p=10^{-7}). Scatterplots showing

the   univariate   relationships   between   the   partner   drug   concentrations   and

primaquine/carboxyprimaquine concentrations are shown in Supplementary Figure 2. Treatment

with   chloroquine   or   piperaquine   had   no   statistically   significant   effect   on   the

carboxyprimaquine/primaquine ratios.

Effect of *CYP 2D6* genotypes

CYP 2D6 genotypes were determined in 154 patients. The estimated *CYP 2D6* allele frequencies

in this population were as follows: 25% for *1; 23% for *2; 2% for *4; 10% for *5; 38% for *10;

0.5% for *39; and 1% for *36. Alleles *4, *5, and *36 are considered null-metabolizer alleles

(enzyme activity score of 0); *10 is a poor metabolizer allele (activity score of 0.25); and *1 and

*39 are normal metabolizer alleles (activity score of 1). In total, there were 3 patients with an

activity score of 0 (non-metabolizers) and 36 patients with activity scores of either 0.25 or 0.5

(poor metabolizers). For primaquine day 7 plasma concentrations, model residuals (defined as

the observed concentration minus the predicted concentration, both on the log scale, where the

model is based on age, mg/kg dose, fever clearance, time since last dose, number of days of

dosing, and partner drug), were correlated significantly with the genotype-defined *CYP 2D6*

enzyme activity scores (Figure 2; ρ= -0.2, p=0.004). Patients with low *CYP 2D6* activity scores had,

on average, higher observed concentrations of primaquine than predicted (i.e. positive

residuals), whereas patients with normal activity scores had lower concentrations than expected

(i.e. negative residuals). For plasma carboxyprimaquine concentrations, a trend in the same

direction was observed, but the correlation was substantially smaller, and it was not significant

(p=0.1).

Methemoglobinemia and hemolysis

Primaquine causes predictable methemoglobinemia. As reported previously methemoglobin

concentrations rose over the first week of primaquine treatment, and then plateaued in the 14-

day primaquine groups. The day 7 values were usually the peak recorded values

(Supplementary Figure 3). Methemoglobin (expressed as a percentage of the hemoglobin

concentration) was lower in children than in young adults ($p<10^{-16}$ for a spline term fit to age in

a generalized additive regression model, Figure 3A), and was lower in patients with loss of

function *CYP 2D6* polymorphisms (Figure 2C; absolute decrease of 1.2 percentage points in the

mean day 7 methemoglobin level in patients with an activity score ≤ 0.5 compared to patients

with an activity score > 0.5; 95% CI: 0.1-2.3%, *p*=0.04). Day 7 methemoglobin levels were

associated with both primaquine and carboxyprimaquine day 7 plasma concentrations. A ten-

fold increase in primaquine day 7 concentrations was associated with an absolute increase of

0.7 percentage points in day 7 methemoglobin levels (95% CI: 0.14-1.23), and a ten-fold

increase in carboxyprimaquine concentrations was associated with an absolute increase of 1.1

percentage points in day 7 methemoglobin levels (95% CI: 0.5 – 2.0). Four patients stopped

taking primaquine because of elevated methemoglobin levels and associated symptoms. Two of

these patients stopped on day 5 and, as the day 6 primaquine dose was not administered, they

had low day 7 primaquine and carboxyprimaquine levels. One of these patients had a recorded

methemoglobin level of 20.9% on day 6 followed by 18.1% on day 7. The other three patients

had peri-oral cyanosis (blue lips). Their peak recorded methemoglobin levels were between 10

and 12%.

There was no relationship between age and hemolysis defined as the percentage drop in

hematocrit between baseline and day 7 (Figure 3B).

Primaquine exposure and *P. vivax* recurrence

We did an exploratory analysis of the relationship between primaquine exposures and times to

the first *P. vivax* recurrence. A total of 564 patients had recorded day 7 drug levels and

methemoglobin levels, and 70 had at least one recurrence during follow-up. After adjusting for

age and partner drug, day 7 concentrations of primaquine and carboxyprimaquine were not

associated with the risk of recurrence, but a 1% absolute increase in day 7 methemoglobin was

associated with a hazard ratio for recurrence of 0.9 (95% CI: 0.85-0.99, p=0.02). Two of the

three patients with a *CYP 2D6* activity score of 0 had a *P. vivax* recurrence, and one of them had

2 recurrences (the interval between recurrences was >65 days). Studies are ongoing to

characterize the relationship between *CYP 2D6* genotypes and risk of *P. vivax* relapse in this

population.

Discussion

Radical cure of *P. vivax* malaria is necessary to prevent relapses. Relapses of vivax malaria are a

major cause of morbidity and developmental delay in children living in endemic areas, so

optimization of primaquine dosing is critical in this age group. The higher *P. vivax* relapse rates in

children compared with adults living in endemic areas observed in some studies (22) are

attributed usually to lower levels of immunity, but lower drug exposures could also be a

contributory factor. For many antimalarial drugs, exposures in children are lower than in adults

and an increase in the weight adjusted dosing is needed (1). The limited pharmacokinetic

evidence to date for primaquine does not provide a clear picture, with a study from Papua New

Guinea suggesting little difference between adults and older children (2), whereas a study of

single dose primaquine (used as a *P. falciparum* gametocytocide) in Tanzania (3) and a study of

primaquine for *P. vivax* radical cure in Brazil (4) both suggesting that younger children had lower

exposures. The relationship between plasma primaquine concentrations and antimalarial effect

is complex. Primaquine is metabolized rapidly (elimination half-life ~5 hours) via monoamine

oxidase to a biologically inert metabolite carboxyprimaquine and, through a separate pathway,

mainly via *CYP 2D6,* to several active hydroxylated metabolites (6, 23). The exact mechanism of

antimalarial action remains uncertain. Recent laboratory studies suggest that these unstable

hydroxylated metabolites are oxidized to quinoneimines generating local hydrogen peroxide -

which is parasiticidal. The quinoneimines in turn are substrates for cytochrome P450

NADPH:oxidoreductase (POR or CPR) resulting in hydrogen peroxide accumulation and

augmenting the parasiticidal effect (24). These reactions may mediate both the antimalarial

therapeutic effects, and also the oxidant hemolytic adverse effects. Alternatively the

quinoneimine itself may cause the hemolytic and possibly parasiticidal effects by forming

irreversible ligands with heme. There is also evidence for synergy between the 8-aminoquinolines

and other quinoline antimalarials in liver stage and blood stage activities (25, 26). The 8-

aminoquinolines have innate schizonticidal activity as well as radical curative activity and 4-

aminoquinoline antimalarials increase primaquine concentrations (15, 16, 26). Unfortunately,

although the metabolic pathway to the production of the active primaquine metabolites has

been characterized ex-vivo, no validated measure of their concentrations, or of their more stable

metabolites, in whole blood, plasma, or urine has yet been correlated with antimalarial

therapeutic responses in-vivo. Thus, measurement of primaquine and carboxyprimaquine

concentrations does not provide a direct correlate of antimalarial activity. Furthermore, because

the apparent volume of distribution of carboxyprimaquine is not known, the proportion of parent

drug that passes through this inactive metabolic pathway cannot be estimated.

This large study of day 7 "trough" primaquine and carboxyprimaquine plasma concentrations

shows clearly that exposures to both parent compound and inactive metabolite are lower in

children than in adults. This is unlikely to be explained by lower oral bioavailability as primaquine

is generally well absorbed, the children in the study were clinically well by seven days after

starting treatment (14), all doses were observed, and only 7 children ≤10 years old (≤27kg)

vomited. It presumably reflects either larger primaquine (and carboxyprimaquine) distribution

volumes, or increased clearance, or both. The lower ratio of carboxyprimaquine to primaquine

in children may also be explained by these age-related pharmacokinetic changes. Although

greater diversion down the bioactivating CYP pathway cannot be excluded as an explanation for

these findings- there is no convincing evidence for augmented drug efficacy (e.g. no relationship

with fever or parasite clearance times) or increased hemolytic toxicity in children to support this.

Furthermore, in this study, methemoglobinemia was lower in children than in young adults,

indicating that formation of oxidant metabolites was reduced (27). Lower methemoglobin

concentrations were associated with an increased risk of *P. vivax* recurrence. The importance of

CYP 2D6 primaquine bioactivation in the generation of oxidant metabolites was evidenced by the

lower levels of methemoglobinemia in patients with loss of function *CYP 2D6* polymorphisms

(Figure 2C). Taken together this evidence strongly suggests that children have lower exposures

to the biologically active metabolites of primaquine than do adults receiving the same weight

adjusted doses.

This study was sufficiently large that the influence of other covariates affecting primaquine

exposures could be examined. We have reported previously that co-administration of quinoline

or structurally related antimalarials increases primaquine and carboxyprimaquine concentrations

(15, 16). This was confirmed in this study. The effects on the parent compound of chloroquine

and piperaquine were similar whereas piperaquine had a larger effect on carboxyprimaquine. In

Asia loss of function *CYP 2D6* genetic polymorphisms (mainly the *10 allele) are common. In this

study low *CYP 2D6* activity scores (derived from the genotype) were associated with higher

primaquine levels and lower levels of methemoglobinemia as would be expected from reduced

metabolic conversion through this bioactivation pathway.

There are several limitations to this study. This analysis is limited to drug concentrations at one

time point during radical cure treatment providing a limited description of drug exposures. Very

young children are under-represented, and the analysis does not include any infants < 1 year old.

In addition, *CYP 2D6* genotyping was not performed in all patients.

There is no evidence that the adverse effects of primaquine are significantly worse in children

than adults. The main therapeutic implication of this large pharmacometric evaluation is that

children may require larger weight adjusted doses of primaquine than adults.

Funding

This work was supported by the Wellcome Trust [grant number 089179/Z/09/Z] to NJW. CSC, JW,

APP, JT, CL, FHN and NJW are supported by the Wellcome Trust [Programme grant number

089179]. CSC, JW, APP, JT, CL, FHN, and NJW are part of the Wellcome Trust Mahidol University

Oxford Tropical Medicine Research Programme funded by the Wellcome Trust.

Acknowledgements

This research was funded by The Wellcome Trust. A CC BY or equivalent license is applied to the

author accepted manuscript arising from this submission, in accordance with the grant's open

access conditions. The authors would like to thank the SMRU staff for their hard work in

running this study and the MORU Clinical Pharmacology Laboratory in Bangkok for their diligent

work in sample processing and drug measurements. Special appreciation goes to the

contributions of Htet Htet Chaw, Nwe Wah Lin, Thida Zin, Say Paw, Naw Eh Shee, Thu Lay Paw,

Rattanporn Raksapraidee, Moo Koo Paw, the data entry team headed by Jacher

Wiladphaingern, the logistics team, and the laboratory teams headed by Kanlaya Sriprawat and

Germana Bancone.

We would also like to thank the Data Safety and Monitoring Board: Bob Taylor, Charles Woodrow,

and Professor Nicholas Day for their time and commitment.

References

1.   World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd Edition. World

Health Organization, Geneva.

2.   Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, Waita E, Batty KT, Siba P, Mueller I,

Davis TME, Betuela I. 2014. Pharmacokinetic properties of single-Dose primaquine in papua new

guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.

Antimicrob Agents Chemother 58:432–439.

3.   Gonçalves BP, Pett H, Tiono AB, Murry D. 2017. Age, weight, and CYP2D6 genotype are major

determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother

Agents Chemother 61:e02590-16.

4.   Vieira MVDF, Matos Lopes TR, Mello AGNC, de Sena LWP, Commons RJ, Vieira JLF. 2020. Doses of

primaquine administered to children with Plasmodium vivax according to an age-based dose

regimen. Pathog Glob Health 114:388–392.

5.   Gogtay N, Karande S, Kadam P, Momin S, Thatte U. 2021. Evaluation of pharmacokinetics of

single-dose primaquine in undernourished versus normally nourished children diagnosed with

Plasmodium vivax malaria in Mumbai. J Postgrad Med 67:75–79.

6.   Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard G a,

Ockenhouse C, Bennett J, Walker L a, Ohrt C, Melendez V. 2013. The metabolism of primaquine

to its active metabolite is dependent on CYP 2D6. Malar J 12:e212.

7.   Neafsey P, Ginsberg G, Hattis D, Sonawane B. 2009. Genetic polymorphism in cytochrome P450

2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev

12:334–361.

8.   McGraw J, Waller D. 2012. Cytochrome P450 variations in different ethnic populations. Expert

Opin Drug Metab Toxicol 8:371–382.

9.   Puaprasert K, Chu C, Saralamba N, Day NPJ, Nosten F, White NJ, Dondorp AM, Imwong M. 2018.

Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen

population study. Malar J 17:427.

10. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC. 2013. Primaquine failure and cytochrome P-

450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:1380–1381.

11. Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty,

Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ,

Sutanto I, Sudoyo H, Setiabudy R. 2018. Association of Impaired Cytochrome P450 2D6 Activity

Genotype and Phenotype with Therapeutic Efficacy of Primaquine Treatment for Latent

Plasmodium vivax Malaria. JAMA Netw Open 1:e181449.

12. Price RN, von Seidlein L, Valecha N, Nosten FH, Baird JK, White NJ. 2014. Global extent of

chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis

14:982–91.

13. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S,

Chand K, Chau NH, Cheah PY, Dong LT, Dhorda M, Degaga TS, Devine A, Ekawati LL, Fahmi F,

Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA,

Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H,

Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A,

Simpson JA, Baird JK, White NJ, Day NP, Price RN. 2019. Short-course primaquine for the radical

cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority

trial. Lancet 394:929–938.

14. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, Thinraow S, Wilairisak P,

Raksapraidee R, Carrara VI, Paw MK, Wiladphaingern J, Proux S, Bancone G, Sriprawat K, Lee SJ,

Jeeyapant A, Watson JA, Tarning J, Imwong M, Nosten F, White NJ. 2018. Chloroquine versus

dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or

14 days in Plasmodium vivax malaria. Clin Infect Dis 68:1311–1319.

15. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W,

Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NPJ, White NJ. 2014. Open-Label Crossover

Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai

Subjects. Antimicrob Agents Chemother 58:7340–7346.

16. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ,

Hanpithakpong W, Hanboonkunupakarn B, Day NPJ, Ashley E a, White NJ. 2014. Pharmacokinetic

interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359.

17. Kaewkhao K, Chotivanich K, Winterberg M, Day NP, Tarning J, Blessborn D. 2019. High sensitivity

methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS.

Bioanalysis 11:333–347.

18. Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. 2005. Development of a

PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential

use. Biotechniques 39:571–574.

19. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity

score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol

Ther 83:234–242.

20. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling M V.,

Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. 2020. Standardizing CYP2D6 Genotype to Phenotype

Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation

Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13:116–124.

21. Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Heng TK, Nou S,

Arsanok M, Sriwichai S, Vanachayangkul P, Lin JT, Manning JE, Jongsakul K, Pichyangkul S,

Satharath P, Smith PL, Dysoley L, Saunders DL, Waters NC. 2020. Prevalence of CYP2D6

genotypes and predicted phenotypes in a cohort of cambodians at high risk for infections with

plasmodium vivax. Am J Trop Med Hyg 103:756–759.

22. Luxemburger C, van Vugt M, Jonathan S, McGready RM, Looareesuwan S, White NJ, Nosten FH.

1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg

93:433–438.

23. Avula B, Tekwani BL, Chaurasiya ND, Fasinu P, Dhammika Nanayakkara NP, Bhandara Herath

HMT, Wang Y-H, Bae J-Y, Khan SI, Elsohly MA, McChesney JD, Zimmerman PA, Khan IA, Walker

LA. 2018. Metabolism of primaquine in normal human volunteers: investigation of phase I and

phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-

quadrupole time-of-flight mass spectrometry. Malar J 17:294.

24. Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, Leung S, Miller AB,

Baker DA, Alano P, Paine MJI, Bhatia SN, O'Neill PM, Ward SA, Biagini GA. 2019. Antimalarial

activity of primaquine operates via a two-step biochemical relay. Nat Commun 10:1–9.

25.   Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation

446   of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med

447   46:301–306.

448   26.   Baird JK. 2019. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev 32:1–68.

449   27.   Umbreit J. 2007. Methemoglobin--it's not just blue: a concise review. Am J Hematol 82:134–144.

451   **Tables and Figures**

452   Table 1. Patient characteristics at enrolment by age group

	Age group			
	≤5 years	6-10 years	11-15 years	≥16 years
	n=34	n=71	n=118	n=418
Chloroquine+Primaquine-7	8 (5%)	22 (13%)	29 (18%)	104 (64%)
Chloroquine+Primaquine-14	10 (6%)	18 (11%)	29 (18%)	103 (65%)
DHAP+Primaquine-7	7 (4%)	15 (10%)	37 (24%)	98 (62%)
DHAP+Primaquine-14	9 (6%)	16 (10%)	23 (14%)	113 (70%)
Median age years (IQR, range)	4 (3.2-5, 1.5-5)	8 (6-10, 5.1-10)	13 (12-14, 11-15)	28 (20-39, 16-63)
Median weight, kg (IQR, range)	14 (12-16, 8-20)	20 (16-23, 13-30)	35 (29-43, 21-57)	52 (47-56, 31-88)
Median Body Mass Index, kg/m^2 (IQR, range)	15 (14-16, 13-18)	14 (14-15, 11-18)	17 (15-18, 12-23)[1]	20 (19-22, 13-36)
History of fever, n (%)	34 (100%)	71 (100%)	118 (100%)	411 (98%)
Median temperature >37.5°C, (IQR, range)	37.5 (36.7-38.2, 36-40)	37.4 (36.8-38.2, 36-40.1)	37.6 (37-38.5, 36-40.9)[1]	37.3 (36.8-38.1, 36-40.9)
Fever clearance; days (range)	0 (0-4)	0 (0-3)	1 (0-2)	0 (0-4)
Geometric mean parasitemia, parasites/µL (range)	3096 (16-40,192)	3633 (16-221,056)	4886 (16-75,109)	3804 (16-816,400)
Parasite clearance, days (range)	2 (1-4)	2 (1-3)	2 (1-4)	2 (1-5)
Gametocytemia, n (%)	23 (68%)	56 (79%)	104 (88%)	352 (84%)
Median chloroquine level[a], ng/mL (range)	54.3 (6.4-115)	50.1 (27.3-138)	56.1 (27.6-161)	77.9 (26.9-248)
Median piperaquine level[a], ng/mL (range)	37.5 (15.3-109)	29.4 (10-7-78.2)	35.3 (7.7-131)	37 (7.3-181)
Median carboxyprimaquine level[a], ng/mL (range)	261 (29-1410)	406 (9-1590)	563 (40-2740)	793 (59-4710)
Median primaquine level[a], ng/mL (range)	3.5 (1.1-43.8)	3.8 (0.9-349)	5.2 (0.9-106)	6.9 (1-293)
Median carboxyprimaquine: primaquine ratio[a], (range)	86 (12-207)	97 (4-256)	98 (23-516)	106 (2-564)

Primaquine-7: primaquine dosing 1 mg/kg/day for 7 days

Primaquine-14: primaquine dosing 0.5 mg/kg/day for 14 days

Numeric superscript denotes the number of missing values

[a] Only data from the first episode are included

Legends to Figures

Figure 1: The effect of age on primaquine and carboxyprimaquine exposures in patients with acute vivax

malaria.

Panel A: age versus mg/kg primaquine daily dose;

Panel B: age versus the primaquine concentration on day 7;

Panel C: age versus the carboxyprimaquine concentration on day 7;

Panel D: age versus the ratio of the day 7 carboxyprimaquine to primaquine concentration.

The black lines show model fits using a generalized additive model with a smooth spline term for age

and adjusting for daily mg/kg dose; number of days of primaquine received, time since last dose, partner

drug and fever clearance time (dashed: mean predicted concentration for 1mg/kg daily; solid: mean

predicted concentration for 0.5 mg/kg daily).

Figure 2: The relationship between *CYP 2D6* genotypes and primaquine and carboxyprimaquine

exposure, and day 7 methemoglobin levels. In panels A and B, the y-axis shows the model residuals

(observed minus predicted) for the main model of exposure (adjusting for age, daily mg/kg primaquine

dose, partner drug, and fever clearance time). In panel C, the y-axis shows the observed day 7

methemoglobin %. In all three panels the x-axis is the activity score predicted from the *CYP 2D6*

diplotype (20). Each box-and-whisker plot shows the median value, the interquartile range and the

range. The box widths are proportional to the square-roots of the number of observations per activity

score.

Figure 3: Age and drug exposure relationships with hemolysis and methemoglobinemia.

Panel A: Age and day 7 methemoglobin

Panel B: Age and the day 7 change in hematocrit from baseline.

Panel C: Day 7 methemoglobin and pre-dose primaquine concentrations.

Panel D: Day 7 methemoglobin and pre-dose carboxyprimaquine concentrations. In panels A&B the

black lines show model fits under a generalized additive model with a smooth spline term for age and

adjusting for daily mg/kg dose; number of days of primaquine received, the time since last dose, and

G6PD deficiency (dashed: mean predicted concentration for 1mg/kg daily; solid: mean predicted

concentration for 0.5 mg/kg daily).

Supplementary Figure 1: time since previous dose versus the primaquine and carboxyprimaquine blood

concentration. The dashed vertical lines show the 5th and 95th quantiles of the time since last dose.

Supplementary Figure 2: Primaquine and carboxyprimaquine log concentrations versus chloroquine and

piperaquine log concentrations measured at the same timepoints. The dashed lines show a univariate

linear regression to highlight the trend.

Supplementary Figure 3: Methemoglobin as function of the time since starting primaquine (black

circles: 0.5 mg/kg target dose for 14 days; red circles: 1 mg/kg target dose for 7 days). We added

random jitter to the time in days for visual clarity.

Supplementary Table 1: Estimated regression coefficients (standard errors) for the linear terms in the

main models. NI: not included. Age is included in these models as a non-linear term and so it is excluded

from this table (effects are shown in Figures 1 & 3). For the time to recurrence model, the coefficients

and standard errors are given on the linear scale (hazard ratio is given by the exponential of the

coefficient).

Figure 1

508
509   *Figure 2*

510
511

Figure 3

514
515   Supplementary Figure 1

517　Supplementary Figure 2

519   Supplementary Figure 3

Outcome variable	Regression type	Dose (mg/kg)	Partner drug	Days of primaquine	Fever clearance (days)	CYP 2D6 activity score < 1	G6PD deficiency	Methb (%)
PQ (log ng/mL)	linear	1.14 (0.06)	0.014 (0.03)	0.038 (0.047)	-0.017 (0.021)	NI	NI	NI
CPQ (log ng/mL)	linear	0.85 (0.040)	-0.020 (0.021)	0.042 (0.032)	-0.027 (0.014)	NI	NI	NI
log CPQ/PQ	linear	-0.28 (0.043)	-0.039 (0.022)	-0.0040 (0.035)	-0.0086 (0.016)	NI	NI	NI
Methb (%)	linear	3.14 (0.92)	NI	-1.11 (0.77)	NI	-1.21 (0.59)	-0.43 (0.86)	NI
Hb reduction (%)	linear	-2.43 (1.43)	-2.90 (0.73)	3.07 (1.13)	-2.10 (0.50)	NI	-12.0 (1.67)	NI
Time to recurrence	Cox proportional hazards	NI	-0.23 (0.24)	NI	NI	NI	NI	-0.09 (0.039)

521   Supplementary Table 1